Press release: Umeå, March 9, 2022. Lipum AB (publ) announce that the company has entered into an agreement with QPS Netherlands BV for the first-in-man phase I-study of the drug candidate SOL-116.

Lipum AB and QPS The Netherlands BV are pleased to announce a collaboration on the first-in-human study of SOL-116 with the aim of becoming a new treatment for chronic inflammatory diseases. QPS, a clinical contract research organization (CRO), was selected for the clinical trial conduct and for bioanalytical support. The combination of clinical facilities both for healthy volunteers and patients, as well as the solid laboratory capabilities made QPS a good candidate for the execution of this exiting program.  

In the randomised, double-blind, placebo-controlled, first-in-human phase I study, safety, tolerability and pharmacokinetics will be evaluated after single ascending doses of SOL-116 in healthy subjects and patients with rheumatoid arthritis. The study will be conducted at QPS facilities in Groningen and Leeuwarden in The Netherlands.

"We are, according to plan, proceeding towards a significant milestone in our development and are indeed looking forward to start clinical studies in collaboration with QPS Netherlands later this year.” – says Einar Pontén, CEO.

For further information, please contact: 

Einar Pontén, CEO
Mobile:   +46 70 578 34 95


Founded in 1995, QPS is a GLP/GCP-compliant contract research organization (CRO) and life sciences products supplier supporting discovery, preclinical, and clinical drug development, providing quality services to pharmaceutical and biotechnology clients worldwide. QPS linearly integrated core competencies include: neuropharmacology, DMPK, toxicology, bioanalysis, translational medicine, and clinical research program management. QPS regional laboratories and testing facilities are located at company headquarters in Newark, DE; Springfield, MO; South Miami, FL, USA; Groningen, The Netherlands; Leeuwarden, The Netherlands; Graz, Austria; Hyderabad, India; and Taipei, Taiwan. For more information, visit: or contact

About Lipum
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email:, phone: +46 8 503 000 50.